Neil Kumar - 03 Dec 2021 Form 4 Insider Report for BridgeBio Pharma, Inc. (BBIO)

Role
CEO and President, Director
Signature
Yi Ching Yau, Attorney-in-Fact
Issuer symbol
BBIO
Transactions as of
03 Dec 2021
Net transactions value
$0
Form type
4
Filing time
07 Dec 2021, 17:14:58 UTC
Previous filing
18 Nov 2021
Next filing
18 Feb 2022
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BBIO Stock Option (right to buy) Award $0 +786,072 $0.000000 786,072 03 Dec 2021 Common Stock 786,072 $38.62 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option vests and becomes exercisable as to 25% of the underlying shares on December 3, 2022 and thereafter in 36 equal monthly installments, subject to the Reporting Person's continued service with the Issuer or any of its subsidiaries through each vesting date.